SGLT2 inhibitors
Metabolic· 16 reviewed drugs· 24679 cited findings behind them
What the regulatory reviews cover
This library includes several SGLT2 inhibitors that have undergone regulatory review. These drugs are indicated for various conditions, primarily focusing on glycemic control in adults and children with type 2 diabetes mellitus, and cardiovascular and renal outcomes. Reviewed SGLT2 inhibitors include Invokana, ertugliflozin, Jardiance, Farxiga, dapagliflozin, Glyxambi, Steglatro, Forxiga, Synjardy, Steglujan, Vokanamet, Xigduo, Qtern, Xigduo XR, Edistride, and Ebymect.
Different drugs were studied in different trials, so figures are not head-to-head comparisons. For example, Invokana showed a Reduction in renal composite endpoint (ESKD, doubling of serum creatinine, and renal death) of 0.66. Jardiance demonstrated an HbA1c reduction (%) of -0.85 %. Farxiga reported a Hazard ratio for composite of hospitalization for heart failure or CV death of 0.83. Steglatro showed an Ertugliflozin IC50 for human SGLT2 of 0.877 ± 0.369.
The drugs — one cited result each
| Invokana Johnson & Johnson | Reduction in renal composite endpoint (ESKD, doubling of serum creatinine, and renal death): 0.66 Johnson & Johnson — Invokana FDA Review (NDA204042, SUPPL 32, p.14 |
| ertugliflozin Merck & Co., Inc. | 3273 cited findings on the drug page → |
| Jardiance Boehringer Ingelheim | HbA1c reduction (%): -0.85 % Boehringer Ingelheim — Jardiance EMA EPAR public assessment, p.50 |
| Farxiga AstraZeneca PLC | Hazard ratio for composite of hospitalization for heart failure or CV death: 0.83 Farxiga FDA Review (NDA/BLA 202293, 2021), p.44 |
| dapagliflozin AstraZeneca PLC | HR for Hospitalisation for HF/CV death (dapagliflozin vs placebo): 0.83 AstraZeneca PLC — Ebymect EMA EPAR variation assessment repo, p.22 |
| Glyxambi Boehringer Ingelheim | MACE Hazard Ratio (95% CI): 1.02 (0.89, 1.17) Glyxambi FDA Review, p.51 |
| Steglatro Merck & Co., Inc. | Ertugliflozin IC50 for human SGLT2: 0.877 ± 0.369 Merck & Co., Inc. — Steglatro EMA EPAR public assessment rep, p.16 |
| Forxiga AstraZeneca PLC | HbA1c change from baseline: -0.72 AstraZeneca PLC — Forxiga EMA EPAR public assessment report, p.63 |
| Synjardy Boehringer Ingelheim | Change from baseline in HbA1c for empagliflozin pooled vs placebo: -0.84 Boehringer Ingelheim — Synjardy EMA EPAR variation assessmen, p.27 |
| Steglujan Merck & Co., Inc. | HbA1c change from baseline: -1.05 Merck & Co., Inc. — Steglujan EMA EPAR public assessment rep, p.62 |
| Vokanamet Johnson & Johnson | HbA1c reduction relative to placebo: -1.16 Johnson & Johnson — Vokanamet EMA EPAR public assessment rep, p.81 |
| Xigduo AstraZeneca PLC | Dapagliflozin AUC0-t Ratio (90% CI): 1.02 (0.998-1.04) AstraZeneca PLC — Xigduo EMA EPAR public assessment report (, p.31 |
| Qtern Astra Zeneca | HbA1c change from baseline (Qtern): -1.47 Astra Zeneca — Qtern EMA EPAR public assessment report (EMEA, p.50 |
| Xigduo XR AstraZeneca PLC | 85 cited findings on the drug page → |
| Edistride AstraZeneca PLC | 35 cited findings on the drug page → |
| Ebymect AstraZeneca PLC | 33 cited findings on the drug page → |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Metabolic research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.